A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Summary

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Timeline

Start

2024-11-21

Primary completion

2028-10-30

Completion

2028-10-30

Drugs

Indications